Iterum Therapeutics plc announced that the first patient has been dosed in its Phase 3 clinical trial, known as REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales (REASSURE), comparing oral sulopenem (sulopenem etzadroxil combined with probenecid in a bilayer tablet) to oral Augmentin(R) (amoxicillin/clavulanate) in adult women with uncomplicated urinary tract infections (uUTI).
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.55 USD | +1.97% | 0.00% | -21.32% |
13/05 | Transcript : Iterum Therapeutics plc, Q1 2024 Earnings Call, May 13, 2024 | |
13/05 | Iterum Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.32% | 25.16M | |
+28.95% | 48.16B | |
-0.40% | 41.73B | |
+43.57% | 41.03B | |
-5.31% | 28.77B | |
+10.77% | 25.59B | |
-21.84% | 18.96B | |
+8.48% | 12.92B | |
+27.48% | 12.03B | |
-2.76% | 11.77B |
- Stock Market
- Equities
- ITRM Stock
- News Iterum Therapeutics plc
- Iterum Announces First Patient Dosed in Reassure, A Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections